United States - English - NLM (National Library of Medicine)

a-s medication solutions - brimonidine tartrate (unii: 4s9cl2dy2h) (brimonidine - unii:e6gnx3hhte) - brimonidine tartrate ophthalmic solution 0.2% is indicated for lowering intraocular pressure (iop) in patients with open-angle glaucoma or ocular hypertension. the iop lowering efficacy of brimonidine tartrate ophthalmic solution diminishes over time in some patients. this loss of effect appears with a variable time of onset in each patient and should be closely monitored. brimonidine tartrate ophthalmic solution is contraindicated in neonates and infants (under the age of 2 years) [see use in specific populations (8.4) ]. brimonidine tartrate ophthalmic solution is contraindicated in patients who have exhibited a hypersensitivity reaction to any component of this medication in the past [see adverse reactions (6.1) and (6.2) ]. pregnancy category b: teratogenicity studies have been performed in animals. brimonidine tartrate was not teratogenic when given orally during gestation days 6 through 15 in rats and days 6 through 18 in rabbits. the highest doses of brimonidine tartrate in rats (2.5 mg/kg/day) and rab

United States - English - NLM (National Library of Medicine)

padagis israel pharmaceuticals ltd - brimonidine tartrate (unii: 4s9cl2dy2h) (brimonidine - unii:e6gnx3hhte) - brimonidine topical gel, 0.33% is an alpha adrenergic agonist indicated for the topical treatment of persistent (nontransient) erythema of rosacea in adults 18 years of age or older. brimonidine topical gel is contraindicated in patients who have experienced a hypersensitivity reaction to any component. reactions have included angioedema, urticarial, and contact dermatitis [see warnings and precautions (5.6) and adverse reactions (6.1, 6.2) ]. pregnancy category b. there are no adequate and well-controlled studies of brimonidine topical gel in pregnant women. in animal studies, brimonidine crossed the placenta and entered into the fetal circulation to a limited extent. brimonidine topical gel should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. brimonidine tartrate was not teratogenic when given at oral doses up to 2.5 mg/kg/day in pregnant rats during gestation days 6 through 15 and 5 mg/kg/day in pregnant rabbits during gestation days 6 through 18. it is n

United States - English - NLM (National Library of Medicine)

bryant ranch prepack - brimonidine tartrate (unii: 4s9cl2dy2h) (brimonidine - unii:e6gnx3hhte) - brimonidine topical gel, 0.33% is an alpha adrenergic agonist indicated for the topical treatment of persistent (nontransient) erythema of rosacea in adults 18 years of age or older. brimonidine topical gel is contraindicated in patients who have experienced a hypersensitivity reaction to any component. reactions have included angioedema, urticarial, and contact dermatitis [see warnings and precautions (5.6) and adverse reactions (6.1, 6.2) ]. pregnancy category b. there are no adequate and well-controlled studies of brimonidine topical gel in pregnant women. in animal studies, brimonidine crossed the placenta and entered into the fetal circulation to a limited extent. brimonidine topical gel should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. brimonidine tartrate was not teratogenic when given at oral doses up to 2.5 mg/kg/day in pregnant rats during gestation days 6 through 15 and 5 mg/kg/day in pregnant rabbits during gestation days 6 through 18. it is n

United States - English - NLM (National Library of Medicine)

ax pharmaceutical corp - brimonidine tartrate (unii: 4s9cl2dy2h) (brimonidine - unii:e6gnx3hhte) - brimonidine 4.95 g in 5 g

United States - English - NLM (National Library of Medicine)

sincerus florida, llc - brimonidine tartrate (unii: 4s9cl2dy2h) (brimonidine - unii:e6gnx3hhte), metronidazole (unii: 140qmo216e) (metronidazole - unii:140qmo216e), niacinamide (unii: 25x51i8rd4) (niacinamide - unii:25x51i8rd4), ivermectin (unii: 8883yp2r6d) (ivermectin - unii:8883yp2r6d) -

United States - English - NLM (National Library of Medicine)

sincerus florida, llc - brimonidine tartrate (unii: 4s9cl2dy2h) (brimonidine - unii:e6gnx3hhte) -

United States - English - NLM (National Library of Medicine)

walgreens company - brimonidine tartrate (unii: 4s9cl2dy2h) (brimonidine - unii:e6gnx3hhte) - redness reliever • relieves redness of the eye due to minor eye irritations • if solution changes color or becomes cloudy - you experience eye pain, changes in vision, continued redness or irritation of the eye - condition worsens or persists for more than 3 days

United States - English - NLM (National Library of Medicine)

alcon laboratories, inc. - brinzolamide (unii: 9451z89515) (brinzolamide - unii:9451z89515), brimonidine tartrate (unii: 4s9cl2dy2h) (brimonidine - unii:e6gnx3hhte) - brinzolamide 10 mg in 1 ml - simbrinza (brinzolamide/brimonidine tartrate ophthalmic suspension) 1%/0.2% is a fixed combination of a carbonic anhydrase inhibitor and an alpha 2 adrenergic receptor agonist indicated for the reduction of elevated intraocular pressure (iop) in patients with open-angle glaucoma or ocular hypertension. simbrinza is contraindicated in patients who are hypersensitive to any component of this product. simbrinza is contraindicated in neonates and infants (under the age of two years) [see use in specific populations (8.4)]. developmental toxicity studies with brinzolamide in rabbits at oral doses of 1, 3, and 6 mg/kg/day (20, 60, and 120 times the recommended human ophthalmic dose) produced maternal toxicity at 6 mg/kg/day and a significant increase in the number of fetal variations, such as accessory skull bones, which was only slightly higher than the historic value at 1 and 6 mg/kg. in rats, statistically decreased body weights of fetuses from dams receiving oral doses of 18 mg/kg/day (180 times the recommended

United States - English - NLM (National Library of Medicine)

novartis pharmaceuticals corporation - brinzolamide (unii: 9451z89515) (brinzolamide - unii:9451z89515), brimonidine tartrate (unii: 4s9cl2dy2h) (brimonidine - unii:e6gnx3hhte) - simbrinza (brinzolamide and brimonidine tartrate ophthalmic suspension) 1% and 0.2% is a fixed combination of a carbonic anhydrase inhibitor and an alpha-2 adrenergic receptor agonist indicated for the reduction of elevated intraocular pressure (iop) in patients with open-angle glaucoma or ocular hypertension. simbrinza is contraindicated in patients who are hypersensitive to any component of this product. simbrinza is contraindicated in neonates and infants (under the age of two years) [see use in specific populations (8.4)] . pregnancy category c: developmental toxicity studies with brinzolamide in rabbits at oral doses of 1, 3, and 6 mg/kg/day (20, 60, and 120 times the recommended human ophthalmic dose) produced maternal toxicity at 6 mg/kg/day and a significant increase in the number of fetal variations, such as accessory skull bones, which was only slightly higher than the historic value at 1 and 6 mg/kg. in rats, statistically decreased body weights of fetuses from dams receiving oral doses of 18 mg/k

United States - English - NLM (National Library of Medicine)

bausch & lomb incorporated - brimonidine tartrate (unii: 4s9cl2dy2h) (brimonidine - unii:e6gnx3hhte) - redness reliever